Drug discovery in the rare disease space is increasingly reliant on collaborations between patient groups, industry, and academia. Charles River Laboratories, the global contract research organization, recently held a symposium in New York City on the need for successful collaborations to advance rare disease drug discovery. Following the symposium, we spoke to Patrick Sweeney, Managing Director of Discovery Sciences at Charles River, about the evolving nature of rare disease collaborations, how that’s changing the way researchers work, and why Charles River believes it can play a unique role in facilitating rare disease collaborations.

1 thought on “RARECast: Charles River Sees Opportunity in Fostering Rare Disease Collaborations”

  1. Kris Borrelli says:

    Is there a latest treatment for a 30yr old girl Kris having Wagners Syndrome for the last 3yrs. Currently on predisoin and treatments every 6mos at Rush Hospl Chicago.

Comments are closed.